MX340846B - Composición de nitazoxanida mejorada y proceso para prepararla. - Google Patents

Composición de nitazoxanida mejorada y proceso para prepararla.

Info

Publication number
MX340846B
MX340846B MX2014008975A MX2014008975A MX340846B MX 340846 B MX340846 B MX 340846B MX 2014008975 A MX2014008975 A MX 2014008975A MX 2014008975 A MX2014008975 A MX 2014008975A MX 340846 B MX340846 B MX 340846B
Authority
MX
Mexico
Prior art keywords
nitazoxanide
composition
granules
preparation
improved
Prior art date
Application number
MX2014008975A
Other languages
English (en)
Other versions
MX2014008975A (es
Inventor
Esteban Alejandro Fiore
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of MX2014008975A publication Critical patent/MX2014008975A/es
Publication of MX340846B publication Critical patent/MX340846B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009Sachets, pouches characterised by the material or function of the envelope
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La presente invención se relaciona a una composición farmacéutica de administración oral de nitazoxanida útil para el tratamiento de infecciones parasitarias intestinales en la forma de gránulos para suspensión, en donde dicha composición contiene: (a) una fracción de liberación inmediata compuesta por gránulos sin recubrimiento o polvo sin granular de nitazoxanida; y (b) una fracción de liberación pH-dependiente formada por gránulos de nitazoxanida recubiertos por uno o más polímeros de solubilidad pH-dependiente.
MX2014008975A 2012-01-27 2012-01-27 Composición de nitazoxanida mejorada y proceso para prepararla. MX340846B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2012/050380 WO2013110975A1 (es) 2012-01-27 2012-01-27 Composición de nitazoxanida mejorada y proceso para prepararla

Publications (2)

Publication Number Publication Date
MX2014008975A MX2014008975A (es) 2014-11-10
MX340846B true MX340846B (es) 2016-07-28

Family

ID=48872931

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008975A MX340846B (es) 2012-01-27 2012-01-27 Composición de nitazoxanida mejorada y proceso para prepararla.

Country Status (10)

Country Link
US (1) US9498441B2 (es)
EP (1) EP2808019B1 (es)
AR (1) AR089764A1 (es)
BR (1) BR112014018149B1 (es)
CL (1) CL2014001983A1 (es)
CR (1) CR20140351A (es)
MX (1) MX340846B (es)
NI (1) NI201400082A (es)
UY (1) UY34457A (es)
WO (1) WO2013110975A1 (es)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657267A (en) 1969-06-20 1972-04-18 Janssen Pharmaceutica Nv Benzimidazole carbamates
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
US5387598A (en) 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
HU229641B1 (en) 1997-05-07 2014-03-28 Romark Lab Pharmaceutical compositions containing tizoxanide and nitazoxanide
US6132461A (en) 1998-03-27 2000-10-17 Intratherapeutics, Inc. Stent with dual support structure
US20040253323A1 (en) * 2003-06-11 2004-12-16 Giles Brian C. Ionic cancer therapy and methods for using same in the treatment of tumors and metastasis
JP4790620B2 (ja) * 2003-11-27 2011-10-12 グリフィス ユニバーシティ 新規な鎮痛性化合物,これを含有する抽出物及びその製造方法
US20050171169A1 (en) 2004-02-02 2005-08-04 Rossignol Jean F. Combination chemotherapy for helminth infections
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8598229B2 (en) * 2005-12-23 2013-12-03 Qbiotics Limited Tiglien-3-one derivatives
CA2636527C (en) 2006-01-09 2016-05-17 Romark Laboratories, L.C. Viral hepatitis treatment
US20080299188A1 (en) 2007-05-14 2008-12-04 Pfizer Inc. Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug
WO2010067140A1 (es) * 2008-12-12 2010-06-17 Siegfried Rhein S.A. De C.V. Composicion de liberacion pulsatil de sildenafil y proceso para prepararla
PL2395840T3 (pl) * 2009-02-13 2020-09-07 Romark Laboratories, L.C. Preparaty farmaceutyczne nitazoksanidu o kontrolowanym uwalnianiu

Also Published As

Publication number Publication date
BR112014018149A8 (pt) 2017-07-11
US20150064262A1 (en) 2015-03-05
BR112014018149A2 (es) 2017-06-20
US9498441B2 (en) 2016-11-22
EP2808019A4 (en) 2015-06-10
UY34457A (es) 2013-09-02
AR089764A1 (es) 2014-09-17
EP2808019B1 (en) 2019-09-25
NI201400082A (es) 2017-03-13
EP2808019A1 (en) 2014-12-03
BR112014018149B1 (pt) 2020-09-29
WO2013110975A1 (es) 2013-08-01
CL2014001983A1 (es) 2015-03-06
CR20140351A (es) 2014-11-05
MX2014008975A (es) 2014-11-10

Similar Documents

Publication Publication Date Title
PH12016501122A1 (en) Delayed release compositions of linaclotide
EP3349762A4 (en) CO-CRYSTALS OF SGLT2 INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
MX348823B (es) Formulaciones estables de linaclotida.
HK1231416A1 (zh) 西羅莫司及其衍生物的絡合物、其製備方法以及含有其的藥物組合物
PH12014501991B1 (en) Phenicol antibacterials
WO2012174158A3 (en) Administration of benzodiazepine
WO2014144295A8 (en) Ceftolozane antibiotic compositions
EP3658124A4 (en) COMPOSITIONS FOR INCREASING THE BIOAVAILABILITY OF MEDICINAL PRODUCTS, SUPPLEMENTS AND INGESTED SUBSTANCES
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
IL272806A (en) The history of boronic acid, its preparation and pharmaceutical preparations containing it
IN2014CH00840A (es)
EP3318259A4 (en) STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
MX364946B (es) Sistema adyuvante mejorado para la administración de vacunas orales.
EP3284743A4 (en) Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof
WO2016063289A3 (en) Pharmaceutical tablet compositions comprising rifaximin
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
WO2015001541A3 (en) Pharmaceutical film composition
EA201400444A1 (ru) Производные 2-оксопиперидинила
EP3290037A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
EP3326628A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION WITH HIGH-CONCENTRATED TAXAN
WO2014128728A3 (en) Solid forms of cabazitaxel and processes for preparation thereof
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide

Legal Events

Date Code Title Description
FG Grant or registration